National Comprehensive Cancer Network



About NCCN

NCCN Guidelines and Compendium Updated

Flash Update Sent March 27, 2012
NCCN has published updates to the NCCN Guidelines for Neuroendocrine Tumors. These NCCN Guidelines are currently available as Version 1.2012.

  • A new section titled, "Principles of Pathology for Diagnosis and Reporting of Neuroendocrine Tumors" was added.
  • Recommendations for surgical management of neuroendocrine tumors of the pancreas were extensively revised.
  • For localized, low-grade adrenal gland tumors, a treatment option of "Consider adjuvant mitotane therapy" was added as a category 3 recommendation.
  • For localized, high-grade adrenal gland tumors, the treatment option of "Consider adjuvant mitotane therapy" was changed from a category 2A to a category 3 recommendation.
  • For Multiple Endocrine Neoplasia (MEN), Type 1-related acromegaly, "pegvisomant" was added as a treatment option after an incomplete resection.
  • Recommendations for patients with MEN 1 and prolactinoma who desire pregnancy now include possible avoidance of surgical resection.
  • The Discussion section was updated to reflect the changes in the algorithm.

 

NCCN has published updates to the NCCN Guidelines for Uterine Neoplasms. These NCCN Guidelines are currently available as Version 3.2012.

  • The Discussion section was updated to reflect the changes in the algorithm.

 

For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.

 

 

 

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved